Non-Metastatic Castrate Resistant Prostate Cancer (nmCRPC) usually leads to metastatic prostate cancer and death. There are no approved treatments for nmCRPC. Apalutamide is a taken-by-mouth androgen receptor inhibitor with antitumor activity in CRPC. There’s a much talked and written about clinical trial called, SPARTAN, that investigated how well Apalutamide works on maintaining metastasis-free survival (MFS) in men with nmCRPC. 1207 participated in this trial. pts were randomized. Apalutamide decreased the risk of distant metastasis or death by 72% , with a median metastatic free survival period of 40.5 (given Apalutamide) vs 16.2 months (control group not given Apalutamide). Apalutamide significantly improved median metastatic free survival by 2 years in men with nmCRPC. These results support using Apalutamide in men with nmCRPC.